Skip to main content

Heat shock protein 60 as a novel therapeutic target for diabetes and rheumatoid arthritis (HSPFORTHERAPY)

Objective

Heat shock proteins are antigens of immune responses in autoimmunity. In experimental models they suppress inflammation and in clinical trials in diabetes and arthritis hsp60 has a proven therapeutic potential. We propose to analyse the underlying mechanisms by monitoring immunity to hsp60 in the models, in patients and during hsp60 peptide trials, with respect to both the adaptive and the innate part of the immune system.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

UTRECHT UNIVERSITY
Address
Yalelaan 1
3584 CL Utrecht
Netherlands

Participants (5)

DEUTSCHE DIABETES FORSCHUNGSGESELLSCHAFT E.V.
Germany
Address
Auf'm Hennekekamp 65
40225 Duesseldorf
PEPTOR LTD
Israel
Address
Kyriat Weizmann, Building 16
76326 Rehovot
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
Address
Hills Road Addenbrooke's Nhs Trust 5
CB2 2QQ Cambridge
UNIVERSITY MEDICAL CENTRE UTRECHT
Netherlands
Address
Lundlaan 6
3584EA Utrecht
WEIZMANN INSTITUTE OF SCIENCE
Israel
Address
Herzel Street 2
76100 Rehovot